Solid formulation for oral administration of olanzapine or its salt e.g. for treating schizophrenia, comprises core of anhydrous olanzapine or its salt coated with functional polymer that acts as filmogenic agent

摘要

A solid oral olanzapine formulation comprises a core of anhydrous olanzapine or its salt as active substance and optionally pharmaceutical excipients. The core is coated with a functional polymer that acts as filmogenic agent. A solid oral olanzapine formulation comprises a core of anhydrous olanzapine of formula (I) or its salt as active substance and optionally pharmaceutical excipients. The core is coated with a functional polymer that acts as filmogenic agent. An independent claim is included for preparation of solid oral formulation by providing anhydrous olanzapine (I) or its salt in solid form (e.g. tablet), preparing a dispersion of functional polymer in aqueous medium (e.g. water), and applying the dispersion to the solid form. [Image] ACTIVITY : Neuroleptic. No biological data given. MECHANISM OF ACTION : Antagonist on dopamine receptor D1-D5; of serotonin 5-HT2 and 5-HT3; alpha -1-adrenergic, cholinergic, and H1 histaminergic.